Seaport Therapeutics
SPTX
Seaport Therapeutics (SPTX) news
Recent news
Seaport Therapeutics, Inc.: H.C. Wainwright initiates coverage with buy rating and target price $50
AInvest Wire · Jul 15, 2026Seaport Therapeutics - Q1 net loss per share $10.34
AInvest Wire · Jun 8, 2026Seaport Therapeutics - to initiate Phase 2A Glyphago trial in second half of 2026
Seaport Therapeutics, a clinical-stage therapeutics company focused on developing novel neuropsychiatric medicines, announced plans to initiate Phase 2a proof-of-pharmacology trial for its lead candidate, GlyphAgo (SPT-320 or Glyph Agomelatine), in the second half of 2026. This decision follows the…
AInvest Wire · Jun 8, 2026Seaport Therapeutics - to initiate Phase 2B Glyphago trial in first half of 2027
AInvest Wire · Jun 8, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.